EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Determinants of chemotherapy abandonment in Ethiopia: a nested case–control study

Tigist Birie, Muluken Gizaw, Edom Seife, Nigussie Assefa Kassaw, Yared Tilahun, Adamu Addissie, Eva J Kantelhardt iD, Sefonias Getachew iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Tigist Birie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Assosa University, College of Health Science, Department of Epidemiology and Biostatistics, Assosa, Ethiopia. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Addis Ababa University, German Academic Exchange Service to Martin Luther University, Else Kröner-Fresenius Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is one of the leading causes of cancer deaths in women worldwide. Systemic treatment can improve survival considerably. Breast cancer patients in many African countries face challenges during treatment and often abandon the recommended cycles of chemotherapy. Therefore, this study aims to describe the magnitude of abandonment and its determinants at 4 tertiary hospitals in Ethiopia.

Methods

An institution-based, nested case–control study was conducted. Initially, a cohort of patients with histologically diagnosed stage I-III breast cancer from 2019 to 2020 were reviewed. Then, a total of 400 patients (200 cases and 200 controls) were selected by simple random sampling from the medical log book. The data was collected from patients’ charts and with a structured telephone interview-based questionnaire. The bivariate and multivariable logistic regression models were used to find the independent determinants.

Results

Out of 1740 patients, 329 (18.9%) abandoned chemotherapy. The identified determinants for chemotherapy abandonment were stage III versus stage I/II adjusted odds ratio (AOR = 2.2, confidence interval (CI): 1.2-3.7), more financial constraints (AOR = 2.1, CI: 1.1-3.8), self-assertion of being healthy (AOR = 3.4, CI: 1.2-9.7), more expectations about side effects (AOR = 8.4, CI: 1.6-44.3), more intolerability of side effects (AOR = 2.0, CI: 1.2-3.5), initiating chemotherapy during COVID 19 (AOR = 3.0, CI: 1.7-5.2), and more fear of dependence on therapy (AOR = 7.8, CI: 4.4-13.9).

Conclusion

Nearly one-fifth of patients who started chemotherapy eventually abandoned their treatment. This means that patients experienced physical and financial toxicity as well as the efforts of health workers, but no treatment benefit. To avoid this, physicians need to closely follow the patients and explain the need to complete all chemotherapy cycles and treat side effects to avoid treatment abandonment with impaired survival. Additionally, attention must be paid to improving patient follow-up care during pandemics like COVID-19 and subsidizing therapy to ensure accessibility. Moreover, attention should be given to improving the subsidization of therapy and ensuring accessibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleEthiopiaCase-Control StudiesMiddle AgedAdultAgedCOVID-19SARS-CoV-2

Stichwörter der Autor:innen

AfricaEthiopiaabandonmentbreast cancerchemotherapyside-effects

Autor:innen und Institutionen

  • Assosa University, College of Health Science, Department of Epidemiology and Biostatistics, Assosa, Ethiopia.
  • Department of Epidemiology and Biostatistics, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
  • Global Health Working Group, Institute of Medical Epidemiology, Martin-Luther-University, 06112 Halle, Germany.
  • NCD Working Group, School of Public Health, Addis Ababa University.
  • Addis Ababa University, Tikur Anbesa Specialized Hospital, Oncology Center, Addis Ababa, Ethiopia.
  • Department of Reproductive, Family and Population Health, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.

ORCID-Profile: Eva J Kantelhardt, Sefonias Getachew

Förderung

  • Addis Ababa University
  • German Academic Exchange Service to Martin Luther University
  • Else Kröner-Fresenius Foundation
  • German Ministry of Research and Education
  • European Union

Zitieren

APA

Birie, T., Gizaw, M., Seife, E., Kassaw, N. A., Tilahun, Y., Addissie, A., Kantelhardt, E. J., & Getachew, S. (2025). Determinants of chemotherapy abandonment in Ethiopia: a nested case–control study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf076

Vancouver

Birie T, Gizaw M, Seife E, Kassaw NA, Tilahun Y, Addissie A, et al. Determinants of chemotherapy abandonment in Ethiopia: a nested case–control study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf076

BibTeX
@article{Birie2025,
  author = {Birie, Tigist and Gizaw, Muluken and Seife, Edom and Kassaw, Nigussie Assefa and Tilahun, Yared and Addissie, Adamu and Kantelhardt, Eva J and Getachew, Sefonias},
  title = {Determinants of chemotherapy abandonment in Ethiopia: a nested case–control study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf076}
}
Kostenlos starten →